| Symbol | ALDX |
|---|---|
| Name | ALDEYRA THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 131 HARTWELL AVENUE,SUITE 320, LEXINGTON, Massachusetts, 02421, United States |
| Telephone | +1 781 761-4904 |
| Fax | — |
| — | |
| Website | https://www.aldeyra.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001341235 |
| Description | Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The companys product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Additional info from NASDAQ: |
2026-07-15 20:46
(99% Neutral) ALDEYRA THERAPEUTICS, INC. (ALDX) Announces Regulatory Update
Read more
2026-06-11 20:27
Miller-Rich Nancy 🟢 acquired 73.3K shares (2 derivative) of Aldeyra Therapeutics, Inc. (ALDX) at $1.72 Transaction Date: Jun 09, 2026 | Filing ID: 267634
Read more
2026-06-11 20:26
DOUGLAS RICHARD 🟢 acquired 92.2K shares (3 derivative) of Aldeyra Therapeutics, Inc. (ALDX) at $1.72 Transaction Date: Jun 09, 2026 | Filing ID: 267629
Read more
2026-06-11 20:25
Phillips Gary M. 🟢 acquired 81.6K shares (3 derivative) of Aldeyra Therapeutics, Inc. (ALDX) at $1.72 Transaction Date: Jun 09, 2026 | Filing ID: 267623
Read more
2026-06-11 20:23
Clark William D 🟢 acquired 72.3K shares (2 derivative) of Aldeyra Therapeutics, Inc. (ALDX) at $1.72 Transaction Date: Jun 09, 2026 | Filing ID: 267611
Read more
2026-06-11 20:21
Walker Neal 🟢 acquired 73.3K shares (2 derivative) of Aldeyra Therapeutics, Inc. (ALDX) at $1.72 Transaction Date: Jun 09, 2026 | Filing ID: 267605
Read more
2026-06-11 20:20
Bronstein Ben 🟢 acquired 80.3K shares (3 derivative) of Aldeyra Therapeutics, Inc. (ALDX) at $1.72 Transaction Date: Jun 09, 2026 | Filing ID: 267600
Read more
2026-06-11 20:18
DEPTULA-HICKS DARLENE M 🟢 acquired 94.3K shares (2 derivative) of Aldeyra Therapeutics, Inc. (ALDX) at $1.72 Transaction Date: Jun 09, 2026 | Filing ID: 267587
Read more
2026-06-11 17:13
New Form 3 - Aldeyra Therapeutics, Inc. <b>Filed:</b> 2026-06-11 <b>AccNo:</b> 0001193125-26-267553 <b>Size:</b> 3 KB
Read more
2026-06-10 00:30
Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07402876 | A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma | Phase3 | Primary Vitreoretinal Lymphoma | Recruiting | 2026-02-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT06685692 | A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol… | Phase2 | Alcohol Hepatitis | Completed | 2024-11-04 | 2025-06-18 | ClinicalTrials.gov |
| NCT06493604 | A Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease | Phase3 | Dry Eye Disease | Completed | 2024-06-24 | 2025-02-27 | ClinicalTrials.gov |
| NCT06424444 | A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Dis… | Phase3 | Dry Eye Disease | Completed | 2024-04-29 | 2024-11-03 | ClinicalTrials.gov |
| NCT06389214 | A Clinical Trial to Assess the Efficacy and Safety of Subjects With Dry Eye Dis… | Phase3 | Dry Eye Disease | Completed | 2024-04-09 | 2024-06-11 | ClinicalTrials.gov |
| NCT05717920 | A Clinical Trial in Subjects With Atopic Dermatitis (Part 1) | Phase2 | Atopic Dermatitis | Completed | 2023-02-15 | 2023-11-21 | ClinicalTrials.gov |
| NCT05599815 | Part 1 - A Clinical Trial in Patients With Frequently Relapsing and Steroid-Dep… | Phase2 | Nephrotic Syndrome | Withdrawn | 2023-01-01 | 2023-05-01 | ClinicalTrials.gov |
| NCT05392179 | A Study in Subjects With Retinitis Pigmentosa | Phase2 | Retinitis Pigmentosa | Completed | 2022-07-14 | 2023-06-23 | ClinicalTrials.gov |
| NCT05392192 | A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic C… | Phase2 | Chronic Cough | Completed | 2022-04-07 | 2023-04-13 | ClinicalTrials.gov |
| NCT05424549 | A Clinical Trial to Evaluate the Safety and Efficacy of Rreproxalap in Adults W… | Phase2 | Dry Eye Syndromes | Completed | 2022-03-09 | 2022-05-09 | ClinicalTrials.gov |
| NCT05234554 | The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of S… | Phase3 | Allergic Conjunctivitis | Completed | 2022-01-21 | 2023-04-22 | ClinicalTrials.gov |
| NCT05487404 | A Clinical Trial to Evaluate the Safety and Efficacy of ADX-629 in in Subjects … | Phase1 | Ethanol Intoxication | Completed | 2021-11-15 | 2022-05-29 | ClinicalTrials.gov |
| NCT05102409 | An Exploratory Crossover Clinical Trial to Compare the Activity of Reproxalap a… | Phase2 | Dry Eye | Completed | 2021-09-09 | 2021-10-25 | ClinicalTrials.gov |
| NCT05062330 | The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Sa… | Phase3 | Dry Eye | Completed | 2021-08-28 | 2022-03-04 | ClinicalTrials.gov |
| NCT04971031 | A Clinical Trial to Assess Subjects With Dry Eye Disease. | Phase2 | Dry Eye | Completed | 2021-06-15 | 2021-09-08 | ClinicalTrials.gov |
| NCT04908514 | A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects… | Phase2 | Plaque Psoriasis | Completed | 2021-05-07 | 2022-01-21 | ClinicalTrials.gov |
| NCT04847544 | A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the … | Phase2 | Covid19 | Completed | 2021-03-31 | 2021-10-15 | ClinicalTrials.gov |
| NCT04735393 | A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group C… | Phase3 | Dry Eye Disease | Completed | 2021-01-26 | 2022-10-11 | ClinicalTrials.gov |
| NCT04728711 | A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial t… | Phase2 | Atopic Asthma | Completed | 2021-01-09 | 2022-01-18 | ClinicalTrials.gov |
| NCT04674358 | The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subj… | Phase2 | Dry Eye | Completed | 2020-11-21 | 2021-09-12 | ClinicalTrials.gov |
| NCT04207736 | The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Sub… | Phase3 | Allergic Conjunctivitis | Completed | 2019-12-05 | 2021-02-16 | ClinicalTrials.gov |
| NCT04136366 | The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferat… | Phase3 | Proliferative Vitreoretinopathy | Completed | 2019-11-15 | 2022-06-14 | ClinicalTrials.gov |
| NCT03916042 | A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, … | Phase2 | Dry Eye | Completed | 2019-04-23 | 2019-11-22 | ClinicalTrials.gov |
| NCT03879863 | The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Veh… | Phase3 | Dry Eye | Completed | 2019-04-16 | 2019-10-04 | ClinicalTrials.gov |
| NCT03709121 | A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasona… | Phase1 | Conjunctivitis, Allergic | Completed | 2018-10-02 | 2019-03-20 | ClinicalTrials.gov |
| NCT03660878 | A Methodology Development Environmental Clinical Trial of Reproxalap in Subject… | Phase1 | Allergic Conjunctivitis | Completed | 2018-09-08 | 2019-11-19 | ClinicalTrials.gov |
| NCT03445650 | RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrom… | Phase3 | Sjogren-Larsson Syndrome | Completed | 2018-07-18 | 2020-01-18 | ClinicalTrials.gov |
| NCT03494504 | ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis | Phase3 | Allergic Conjunctivitis | Completed | 2018-03-30 | 2018-11-05 | ClinicalTrials.gov |
| NCT03404115 | A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, … | Phase2 | Dry Eye Syndrome | Completed | 2018-01-02 | 2018-07-11 | ClinicalTrials.gov |
| NCT03162783 | A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome | Phase2 | Dry Eye Syndromes | Completed | 2017-05-15 | 2017-07-06 | ClinicalTrials.gov |
| NCT03131154 | SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis. | Phase3 | Non-infectious Anterior Uveitis | Completed | 2017-04-26 | 2019-04-26 | ClinicalTrials.gov |
| NCT03012165 | A Study of ADX-102 in Subjects With Allergic Conjunctivitis | Phase2 | Conjunctivitis, Allergic | Completed | 2016-12-01 | 2017-05-01 | ClinicalTrials.gov |
| NCT02578914 | A Safety and Activity Study of NS2 in Subjects With Allergic Conjunctivitis | Phase2 | Allergic Conjunctivitis | Completed | 2015-08-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02402309 | A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (S… | Phase2 | Sjögren-Larsson Syndrome | Completed | 2015-03-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT02406209 | A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis | Phase2 | Non-infectious Anterior Uveitis | Completed | 2015-03-01 | 2016-04-01 | ClinicalTrials.gov |
Total clinical trials: 35
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| ADX-629 | Other | Phase PHASE2 | Alcohol Hepatitis | COMPLETED | NCT06685692 |
| Vehicle Ophthalmic Solution | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT05234554 |
| Reproxalap Ophthalmic Solution (0.25%) | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT05234554 |
| Vehicle Ophthalmic Solution | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT05234554 |
| Reproxalap Ophthalmic Solution (0.25%) | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT05234554 |
| Vehicle Ophthalmic Solution | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT05234554 |
| Reproxalap Ophthalmic Solution (0.25%) | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT05234554 |
| Vehicle Ophthalmic Solution | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT05234554 |
| Reproxalap Ophthalmic Solution (0.25%) | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT05234554 |
| Vehicle Ophthalmic Solution | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT05234554 |
| Reproxalap Ophthalmic Solution (0.25%) | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT05234554 |
| Vehicle Ophthalmic Solution | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT05234554 |
| Reproxalap Ophthalmic Solution (0.25%) | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT05234554 |
| Vehicle Ophthalmic Solution | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT05234554 |
| Reproxalap Ophthalmic Solution (0.25%) | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT05234554 |
| Vehicle Ophthalmic Solution | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT05234554 |
| Reproxalap Ophthalmic Solution (0.25%) | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT05234554 |
| Vehicle Ophthalmic Solution | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT04207736 |
| Reproxalap Ophthalmic Solution (0.25%) | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT04207736 |
| Vehicle Ophthalmic Solution | Other | Phase PHASE2 | Dry Eye Syndromes | COMPLETED | NCT05424549 |
| Reproxalap Ophthalmic Solution (0.25%) | Other | Phase PHASE2 | Dry Eye Syndromes | COMPLETED | NCT05424549 |
| Vehicle placebo 0.0% NS2 dermatologic cream | Other | Phase PHASE2 | Sjögren-Larsson Syndrome | COMPLETED | NCT02402309 |
| Active topical NS2 1% dermatologic cream | Other | Phase PHASE2 | Sjögren-Larsson Syndrome | COMPLETED | NCT02402309 |
| Vehicle of ADX-102 Ophthalmic Drops | Other | Phase PHASE2 | Conjunctivitis, Allergic | COMPLETED | NCT03012165 |
| ADX-102 Ophthalmic Drops (0.1%) | Other | Phase PHASE2 | Conjunctivitis, Allergic | COMPLETED | NCT03012165 |
| ADX-102 Ophthalmic Drops (0.5%) | Other | Phase PHASE2 | Conjunctivitis, Allergic | COMPLETED | NCT03012165 |
| Vehicle of ADX-102 Topical Dermal Cream | Other | Phase PHASE3 | Sjogren-Larsson Syndrome | COMPLETED | NCT03445650 |
| ADX-102 1% Topical Dermal Cream (reproxalap) | Other | Phase PHASE3 | Sjogren-Larsson Syndrome | COMPLETED | NCT03445650 |
| Prednisolone acetate ophthalmic suspension (1%) | Other | Phase PHASE2 | Non-infectious Anterior Uveitis | COMPLETED | NCT02406209 |
| NS2 | Other | Phase PHASE2 | Non-infectious Anterior Uveitis | COMPLETED | NCT02406209 |
| NS2 Ophthalmic Drops Vehicle (0.0%) | Other | Phase PHASE2 | Allergic Conjunctivitis | COMPLETED | NCT02578914 |
| NS2 Ophthalmic Drops (0.5%) | Other | Phase PHASE2 | Allergic Conjunctivitis | COMPLETED | NCT02578914 |
| ADX-629 | Other | Phase PHASE2 | Nephrotic Syndrome | WITHDRAWN | NCT05599815 |
| Vehicle Ophthalmic Solution | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT05234554 |
| Reproxalap Ophthalmic Solution (0.25%) | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT05234554 |
| ADX-629 (Open-label) | Other | Phase PHASE2 | Atopic Dermatitis | COMPLETED | NCT05717920 |
| ADX-102 Ophthalmic Lipid Solution (0.5%) | Other | Phase PHASE2 | Dry Eye Syndromes | COMPLETED | NCT03162783 |
| ADX-102 Ophthalmic Solution (0.1%) | Other | Phase PHASE2 | Dry Eye Syndromes | COMPLETED | NCT03162783 |
| ADX-102 Ophthalmic Solution (0.5%) | Other | Phase PHASE2 | Dry Eye Syndromes | COMPLETED | NCT03162783 |
| Vehicle Ophthalmic Solution QID to BID | Other | Phase PHASE3 | Dry Eye | COMPLETED | NCT03879863 |
| Reproxalap Ophthalmic Solution (0.25%) QID to BID | Other | Phase PHASE3 | Dry Eye | COMPLETED | NCT03879863 |
| Vehicle Ophthalmic Solution QID | Other | Phase PHASE3 | Dry Eye | COMPLETED | NCT03879863 |
| Reproxalap Ophthalmic Solution (0.25%) QID | Other | Phase PHASE3 | Dry Eye | COMPLETED | NCT03879863 |
| Vehicle Ophthalmic Solution | Other | Phase PHASE2 | Dry Eye Syndrome | COMPLETED | NCT03404115 |
| Reproxalap Ophthalmic Solution (0.1%) | Other | Phase PHASE2 | Dry Eye Syndrome | COMPLETED | NCT03404115 |
| Reproxalap Ophthalmic Solution (0.25%) | Other | Phase PHASE2 | Dry Eye Syndrome | COMPLETED | NCT03404115 |
| Vehicle of ADX-102 Ophthalmic Solution | Other | Phase PHASE3 | Non-infectious Anterior Uveitis | COMPLETED | NCT03131154 |
| ADX-102 Ophthalmic Solution (0.5%) | Other | Phase PHASE3 | Non-infectious Anterior Uveitis | COMPLETED | NCT03131154 |
| Vehicle Ophthalmic Solution | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT03494504 |
| Reproxalap Ophthalmic Solution (0.5%) | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT03494504 |
| Reproxalap Ophthalmic Solution (0.25%) | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT03494504 |
| Placebo | Other | Phase PHASE2 | Covid19 | COMPLETED | NCT04847544 |
| ADX-629 | Other | Phase PHASE2 | Covid19 | COMPLETED | NCT04847544 |
| Placebo | Other | Phase PHASE2 | Atopic Asthma | COMPLETED | NCT04728711 |
| ADX-629 | Other | Phase PHASE2 | Atopic Asthma | COMPLETED | NCT04728711 |
| Vehicle Ophthalmic Solution | Other | Phase PHASE2 | Dry Eye | COMPLETED | NCT04971031 |
| Reproxalap Ophthalmic Solution (0.25%) | Other | Phase PHASE2 | Dry Eye | COMPLETED | NCT04971031 |
| Vehicle Ophthalmic Solution | Other | Phase PHASE1 | Conjunctivitis, Allergic | COMPLETED | NCT03709121 |
| Reproxalap Ophthalmic Solution (0.5%) | Other | Phase PHASE1 | Conjunctivitis, Allergic | COMPLETED | NCT03709121 |
| Reproxalap Ophthalmic Solution (0.25%) | Other | Phase PHASE1 | Conjunctivitis, Allergic | COMPLETED | NCT03709121 |
| Placebo | Other | Phase PHASE1 | Ethanol Intoxication | COMPLETED | NCT05487404 |
| ADX-629 | Other | Phase PHASE1 | Ethanol Intoxication | COMPLETED | NCT05487404 |
| Placebo | Other | Phase PHASE2 | Chronic Cough | COMPLETED | NCT05392192 |
| ADX-629 | Other | Phase PHASE2 | Chronic Cough | COMPLETED | NCT05392192 |
| Xiidra® (5% lifitegrast ophthalmic solution) | Other | Phase PHASE2 | Dry Eye | COMPLETED | NCT05102409 |
| Reproxalap Ophthalmic Solution (0.25%) | Other | Phase PHASE2 | Dry Eye | COMPLETED | NCT05102409 |
| Vehicle Ophthalmic Solution (0.25% Novel Formulation) QID to BID | Other | Phase PHASE2 | Dry Eye | COMPLETED | NCT03916042 |
| Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID | Other | Phase PHASE2 | Dry Eye | COMPLETED | NCT03916042 |
| ADX-629 | Other | Phase PHASE2 | Plaque Psoriasis | COMPLETED | NCT04908514 |
| Vehicle Ophthalmic Solution | Other | Phase PHASE3 | Dry Eye | COMPLETED | NCT05062330 |
| Reproxalap Ophthalmic Solution (0.25%) | Other | Phase PHASE3 | Dry Eye | COMPLETED | NCT05062330 |
| Vehicle Opthalmic Solution | Other | Phase PHASE2 | Dry Eye | COMPLETED | NCT04674358 |
| Reproxalap Ophthalmic Solution (0.25%) | Other | Phase PHASE2 | Dry Eye | COMPLETED | NCT04674358 |
| Vehicle Ophthalmic Solution | Other | Phase PHASE1 | Allergic Conjunctivitis | COMPLETED | NCT03660878 |
| Reproxalap Ophthalmic Solution (0.5%) | Other | Phase PHASE1 | Allergic Conjunctivitis | COMPLETED | NCT03660878 |
| Reproxalap Ophthalmic Solution (0.25%) | Other | Phase PHASE1 | Allergic Conjunctivitis | COMPLETED | NCT03660878 |
| Vehicle Ophthalmic Solution | Other | Phase PHASE3 | Dry Eye Disease | COMPLETED | NCT06389214 |
| Reproxalap Ophthalmic Solution (0.25%) | Other | Phase PHASE3 | Dry Eye Disease | COMPLETED | NCT06389214 |
| Standard surgical care procedure | Procedure | Phase PHASE3 | Proliferative Vitreoretinopathy | COMPLETED | NCT04136366 |
| ADX-2191 (intravitreal methotrexate 0.8%) | Other | Phase PHASE3 | Proliferative Vitreoretinopathy | COMPLETED | NCT04136366 |
| Placebo Comparator | Other | Phase PHASE3 | Dry Eye Disease | COMPLETED | NCT04735393 |
| Reproxalap Ophthalmic Solution (0.25%) | Other | Phase PHASE3 | Dry Eye Disease | COMPLETED | NCT04735393 |
| Vehicle ophthalmic solution | Other | Phase PHASE3 | Dry Eye Disease | COMPLETED | NCT06424444 |
| Reproxalap ophthalmic solution (0.25%) | Other | Phase PHASE3 | Dry Eye Disease | COMPLETED | NCT06424444 |
| ADX-629 | Other | Phase PHASE2 | Alcohol Hepatitis | COMPLETED | NCT06685692 |
| Vehicle Ophthalmic Solution | Other | Phase PHASE3 | Dry Eye Disease | COMPLETED | NCT06493604 |
| Reproxalap Ophthalmic Solution (0.25%) | Other | Phase PHASE3 | Dry Eye Disease | COMPLETED | NCT06493604 |
| Monthly ADX-2191 injection | Other | Phase PHASE3 | Primary Vitreoretinal Lymphoma | RECRUITING | NCT07402876 |
| ICM ADX-2191 injection | Other | Phase PHASE3 | Primary Vitreoretinal Lymphoma | RECRUITING | NCT07402876 |
| ADX-2191 | Other | Phase PHASE2 | Retinitis Pigmentosa | COMPLETED | NCT05392179 |
| ADX-2191 | Other | Phase PHASE2 | Retinitis Pigmentosa | COMPLETED | NCT05392179 |
| ADX-2191 | Other | Phase PHASE2 | Retinitis Pigmentosa | COMPLETED | NCT05392179 |
| ADX-2191 | Other | Phase PHASE2 | Retinitis Pigmentosa | COMPLETED | NCT05392179 |
| ADX-2191 | Other | Phase PHASE2 | Retinitis Pigmentosa | COMPLETED | NCT05392179 |
| ADX-2191 | Other | Phase PHASE2 | Retinitis Pigmentosa | COMPLETED | NCT05392179 |
| ADX-2191 | Other | Phase PHASE2 | Retinitis Pigmentosa | COMPLETED | NCT05392179 |
| ADX-2191 | Other | Phase PHASE2 | Retinitis Pigmentosa | COMPLETED | NCT05392179 |
| ADX-2191 | Other | Phase PHASE2 | Retinitis Pigmentosa | COMPLETED | NCT05392179 |
| ADX-2191 | Other | Phase PHASE2 | Retinitis Pigmentosa | COMPLETED | NCT05392179 |
| ADX-2191 | Other | Phase PHASE2 | Retinitis Pigmentosa | COMPLETED | NCT05392179 |
| ADX-2191 | Other | Phase PHASE2 | Retinitis Pigmentosa | COMPLETED | NCT05392179 |
| Monthly ADX-2191 injection | DRUG | Phase PHASE3 | Primary Vitreoretinal Lymphoma | RECRUITING | NCT07402876 |
| ICM ADX-2191 injection | DRUG | Phase PHASE3 | Primary Vitreoretinal Lymphoma | RECRUITING | NCT07402876 |
| Vehicle ophthalmic solution | DRUG | Phase PHASE3 | Dry Eye Disease | COMPLETED | NCT06424444 |
| Reproxalap ophthalmic solution (0.25%) | DRUG | Phase PHASE3 | Dry Eye Disease | COMPLETED | NCT06424444 |
| ADX-629 (Open-label) | DRUG | Phase PHASE2 | Atopic Dermatitis | COMPLETED | NCT05717920 |
| ADX-2191 | DRUG | Phase PHASE2 | Retinitis Pigmentosa | COMPLETED | NCT05392179 |
| Xiidra® (5% lifitegrast ophthalmic solution) | DRUG | Phase PHASE2 | Dry Eye | COMPLETED | NCT05102409 |
| Placebo Comparator | DRUG | Phase PHASE3 | Dry Eye Disease | COMPLETED | NCT04735393 |
| Placebo | DRUG | Phase PHASE1 | Ethanol Intoxication | COMPLETED | NCT05487404 |
| ADX-629 | DRUG | Phase PHASE2 | Alcohol Hepatitis | COMPLETED | NCT06685692 |
| Vehicle Opthalmic Solution | DRUG | Phase PHASE2 | Dry Eye | COMPLETED | NCT04674358 |
| Standard surgical care procedure | OTHER | Phase PHASE3 | Proliferative Vitreoretinopathy | COMPLETED | NCT04136366 |
| ADX-2191 (intravitreal methotrexate 0.8%) | DRUG | Phase PHASE3 | Proliferative Vitreoretinopathy | COMPLETED | NCT04136366 |
| Vehicle Ophthalmic Solution (0.25% Novel Formulation) QID to BID | DRUG | Phase PHASE2 | Dry Eye | COMPLETED | NCT03916042 |
| Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID | DRUG | Phase PHASE2 | Dry Eye | COMPLETED | NCT03916042 |
| Vehicle Ophthalmic Solution QID to BID | DRUG | Phase PHASE3 | Dry Eye | COMPLETED | NCT03879863 |
| Reproxalap Ophthalmic Solution (0.25%) QID to BID | DRUG | Phase PHASE3 | Dry Eye | COMPLETED | NCT03879863 |
| Vehicle Ophthalmic Solution QID | DRUG | Phase PHASE3 | Dry Eye | COMPLETED | NCT03879863 |
| Reproxalap Ophthalmic Solution (0.25%) QID | DRUG | Phase PHASE3 | Dry Eye | COMPLETED | NCT03879863 |
| Reproxalap Ophthalmic Solution (0.5%) | DRUG | Phase PHASE1 | Conjunctivitis, Allergic | COMPLETED | NCT03709121 |
| Vehicle of ADX-102 Topical Dermal Cream | DRUG | Phase PHASE3 | Sjogren-Larsson Syndrome | COMPLETED | NCT03445650 |
| ADX-102 1% Topical Dermal Cream (reproxalap) | DRUG | Phase PHASE3 | Sjogren-Larsson Syndrome | COMPLETED | NCT03445650 |
| Vehicle Ophthalmic Solution | DRUG | Phase PHASE3 | Dry Eye Disease | COMPLETED | NCT06493604 |
| Reproxalap Ophthalmic Solution (0.1%) | DRUG | Phase PHASE2 | Dry Eye Syndrome | COMPLETED | NCT03404115 |
| Reproxalap Ophthalmic Solution (0.25%) | DRUG | Phase PHASE3 | Dry Eye Disease | COMPLETED | NCT06493604 |
| ADX-102 Ophthalmic Lipid Solution (0.5%) | DRUG | Phase PHASE2 | Dry Eye Syndromes | COMPLETED | NCT03162783 |
| ADX-102 Ophthalmic Solution (0.1%) | DRUG | Phase PHASE2 | Dry Eye Syndromes | COMPLETED | NCT03162783 |
| Vehicle of ADX-102 Ophthalmic Solution | DRUG | Phase PHASE3 | Non-infectious Anterior Uveitis | COMPLETED | NCT03131154 |
| ADX-102 Ophthalmic Solution (0.5%) | DRUG | Phase PHASE2 | Dry Eye Syndromes | COMPLETED | NCT03162783 |
| Vehicle of ADX-102 Ophthalmic Drops | DRUG | Phase PHASE2 | Conjunctivitis, Allergic | COMPLETED | NCT03012165 |
| ADX-102 Ophthalmic Drops (0.1%) | DRUG | Phase PHASE2 | Conjunctivitis, Allergic | COMPLETED | NCT03012165 |
| ADX-102 Ophthalmic Drops (0.5%) | DRUG | Phase PHASE2 | Conjunctivitis, Allergic | COMPLETED | NCT03012165 |
| NS2 Ophthalmic Drops Vehicle (0.0%) | DRUG | Phase PHASE2 | Allergic Conjunctivitis | COMPLETED | NCT02578914 |
| NS2 Ophthalmic Drops (0.5%) | DRUG | Phase PHASE2 | Allergic Conjunctivitis | COMPLETED | NCT02578914 |
| Prednisolone acetate ophthalmic suspension (1%) | DRUG | Phase PHASE2 | Non-infectious Anterior Uveitis | COMPLETED | NCT02406209 |
| NS2 | DRUG | Phase PHASE2 | Non-infectious Anterior Uveitis | COMPLETED | NCT02406209 |
| Vehicle placebo 0.0% NS2 dermatologic cream | DRUG | Phase PHASE2 | Sjögren-Larsson Syndrome | COMPLETED | NCT02402309 |
| Active topical NS2 1% dermatologic cream | DRUG | Phase PHASE2 | Sjögren-Larsson Syndrome | COMPLETED | NCT02402309 |
Total products: 139